Data / Drug companies / Neostigmine methylsulfate
Neostigmine methylsulfate: 24 companies and 49 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Neostigmine methylsulfate is listed in the FDA National Drug Code Directory by 24 companies, with 49 products in commercial distribution. 41 of the products (83.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection; injection, solution, and the newest product started marketing on November 6, 2023.
The request: Get every company that lists neostigmine methylsulfate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 24
- Products
- 49
- Generic (ANDA) products
- 41 (83.7%)
- Application numbers
- 14
- Routes
- Intravenous
- Brand names
- Bloxiverz
- openFDA record search
- api.fda.gov
Companies that list neostigmine methylsulfate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | 5 | injection | Generic drugs (ANDA) | December 28, 2015 |
| Fresenius Kabi USA, LLC | 4 | injection, solution | New drug applications (NDA) | January 8, 2015 |
| Medical Purchasing Solutions, LLC | 4 | injection | Generic drugs (ANDA) | January 10, 2022 |
| Amneal Pharmaceuticals LLC | 2 | injection | Generic drugs (ANDA) | June 20, 2018 |
| Amphastar Pharmaceuticals, Inc. | 2 | injection | Generic drugs (ANDA) | September 25, 2017 |
| Be Pharmaceuticals Inc. | 2 | injection | Generic drugs (ANDA) | May 13, 2019 |
| Camber Pharmaceuticals, Inc. | 2 | injection | Generic drugs (ANDA) | January 4, 2021 |
| Caplin Steriles Limited | 2 | injection | Generic drugs (ANDA) | April 30, 2021 |
| Eugia US LLC | 2 | injection | Generic drugs (ANDA) | November 2, 2023 |
| Fresenius Kabi USA, LLC | 2 | injection, solution | New drug applications (NDA) | September 18, 2018 |
| Gland Pharma Limited | 2 | injection | Generic drugs (ANDA) | October 21, 2019 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 2 | injection | Generic drugs (ANDA) | November 25, 2022 |
| Indoco Remedies Limited | 2 | injection | Generic drugs (ANDA) | November 26, 2021 |
| Meitheal Pharmaceuticals Inc. | 2 | injection | Generic drugs (ANDA) | April 5, 2021 |
| Par Health USA, LLC | 2 | injection | Generic drugs (ANDA) | April 26, 2017 |
| Somerset Therapeutics, LLC | 2 | injection | Generic drugs (ANDA) | January 10, 2022 |
| Xellia Pharmaceuticals USA LLC | 2 | injection | Generic drugs (ANDA) | January 10, 2021 |
| Xiromed, LLC | 2 | injection | Generic drugs (ANDA) | September 9, 2020 |
| Civica, Inc. | 1 | injection | Generic drugs (ANDA) | April 16, 2020 |
| Dr. Reddy's Laboratories Inc. | 1 | injection, solution | Generic drugs (ANDA) | July 25, 2022 |
| Exela Pharma Sciences, LLC | 1 | injection | New drug applications (NDA) | November 6, 2023 |
| Fresenius Kabi USA, LLC | 1 | injection, solution | New drug applications (NDA) | January 8, 2015 |
| HF Acquisition Co LLC, DBA HealthFirst | 1 | injection | Generic drugs (ANDA) | June 14, 2021 |
| ProPharma Distribution | 1 | injection | Generic drugs (ANDA) | September 9, 2020 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 41 | 83.7% |
| Injection, solution | 8 | 16.3% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 41 | 83.7% |
| New drug applications (NDA) | 8 | 16.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Cholinesterase Inhibitor | 49 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.